Brief: NeuroBo Pharmaceuticals Doses First Patient In Its Phase 1 Clinical Trial Evaluating DA-1726 For The Treatment Of Obesity

MetaVia

17/04/2024 13:10

April 17 (Reuters) - Neurobo Pharmaceuticals Inc
 NRBO.O :
    * NEUROBO PHARMACEUTICALS DOSES FIRST PATIENT IN ITS PHASE 1
CLINICAL TRIAL EVALUATING DA-1726 FOR THE TREATMENT OF OBESITY
    * NEUROBO PHARMACEUTICALS INC - TOP-LINE DATA READOUT FROM
SINGLE
ASCENDING DOSE PART 1 NOW EXPECTED IN Q3 OF 2024
    * NEUROBO PHARMACEUTICALS INC - FIRST PATIENT DOSED IN
MULTIPLE
ASCENDING DOSE PART 2 EXPECTED IN Q3 OF 2024

Source text for Eikon:  ID:nPn5NnBpVa 
Further company coverage:  NRBO.O